Abstract：
Ceftolozane-tazobactam is a novel cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacteria (GNB). We aimed to comprehensively evaluate the clinical efficacy and safety of ceftolozane-tazobactam in treating GNB infections in adult patients.
PubMed, Embase, and Cochrane databases were retrieved until August 2022. Randomized trials and non-randomized controlled studies evaluating ceftolozane-tazobactam and its comparators in adult patients with GNB infections were included.
A total of 13 studies were included. Overall, patients receiving ceftolozane-tazobactam had significant advantages in clinical cure (odds ratio [OR], 1.62; 95% CI, 1.05-2.51) and microbiological eradication (OR, 1.43; 95% CI, 1.19-1.71), especially in Pseudomonas aeruginosa-infected patients. Ceftolozane-tazobactam had a significant advantage in clinical success or microbial eradication compared with polymyxin/aminoglycosides (PL/AG) or levofloxacin. There were no significant differences in adverse events (AEs), Clostridium difficile infection (CDI), and mortality between ceftolozane-tazobactam and comparators. Notably, ceftolozane-tazobactam showed a significantly lower risk of acute kidney injury compared with PL/AG.
Ceftolozane-tazobactam showed excellent clinical and microbiological efficacy in treating GNB, especially P. aeruginosa-induced infections. The overall safety profile of ceftolozane-tazobactam was comparable to other antimicrobials, with no increased risk of CDI and obvious advantage over antibacterial agents with high nephrotoxicity.
PubMed, Embase, and Cochrane databases were retrieved until August 2022. Randomized trials and non-randomized controlled studies evaluating ceftolozane-tazobactam and its comparators in adult patients with GNB infections were included.
A total of 13 studies were included. Overall, patients receiving ceftolozane-tazobactam had significant advantages in clinical cure (odds ratio [OR], 1.62; 95% CI, 1.05-2.51) and microbiological eradication (OR, 1.43; 95% CI, 1.19-1.71), especially in Pseudomonas aeruginosa-infected patients. Ceftolozane-tazobactam had a significant advantage in clinical success or microbial eradication compared with polymyxin/aminoglycosides (PL/AG) or levofloxacin. There were no significant differences in adverse events (AEs), Clostridium difficile infection (CDI), and mortality between ceftolozane-tazobactam and comparators. Notably, ceftolozane-tazobactam showed a significantly lower risk of acute kidney injury compared with PL/AG.
Ceftolozane-tazobactam showed excellent clinical and microbiological efficacy in treating GNB, especially P. aeruginosa-induced infections. The overall safety profile of ceftolozane-tazobactam was comparable to other antimicrobials, with no increased risk of CDI and obvious advantage over antibacterial agents with high nephrotoxicity.
摘要：
UNASSIGNED：头孢特洛扎-他唑巴坦是一种新型头孢菌素/β-内酰胺酶抑制剂组合，具有抗革兰氏阴性菌（GNB）的活性。本研究旨在综合评价头孢洛扎-他唑巴坦治疗成年患者GNB感染的临床疗效和安全性。
未经授权：PubMed，Embase,和Cochrane数据库检索到2022年8月。纳入了评估成人GNB感染患者头孢特洛赞-他唑巴坦及其比较物的随机试验和非随机对照研究。
UNASSIGNED：共纳入13项研究，共4,167名患者。总的来说,接受头孢特洛赞-他唑巴坦的患者在临床治疗中具有显着的优势（优势比[OR]，1.62；95%CI，1.05-2.51）和微生物根除（OR，1.43；95%CI，1.19-1.71），尤其是铜绿假单胞菌感染的患者。与多粘菌素/氨基糖苷类（PL/AG）或左氧氟沙星相比，头孢洛扎-他唑巴坦在临床成功或微生物根除方面具有显着优势。不良事件（AE）无显著差异，艰难梭菌感染(CDI),头孢特洛扎-他唑巴坦和比较者之间的死亡率。值得注意的是,头孢洛赞-他唑巴坦与PL/AG相比，急性肾损伤的风险明显降低。
未经评估：头孢洛扎-他唑巴坦在治疗GNB方面表现出优异的临床和微生物学疗效，尤其是铜绿假单胞菌引起的感染。头孢洛扎-他唑巴坦的总体安全性与其他抗菌药物相当，CDI的风险没有增加，与高肾毒性的抗菌药物相比具有明显优势。
未经授权：PubMed，Embase,和Cochrane数据库检索到2022年8月。纳入了评估成人GNB感染患者头孢特洛赞-他唑巴坦及其比较物的随机试验和非随机对照研究。
UNASSIGNED：共纳入13项研究，共4,167名患者。总的来说,接受头孢特洛赞-他唑巴坦的患者在临床治疗中具有显着的优势（优势比[OR]，1.62；95%CI，1.05-2.51）和微生物根除（OR，1.43；95%CI，1.19-1.71），尤其是铜绿假单胞菌感染的患者。与多粘菌素/氨基糖苷类（PL/AG）或左氧氟沙星相比，头孢洛扎-他唑巴坦在临床成功或微生物根除方面具有显着优势。不良事件（AE）无显著差异，艰难梭菌感染(CDI),头孢特洛扎-他唑巴坦和比较者之间的死亡率。值得注意的是,头孢洛赞-他唑巴坦与PL/AG相比，急性肾损伤的风险明显降低。
未经评估：头孢洛扎-他唑巴坦在治疗GNB方面表现出优异的临床和微生物学疗效，尤其是铜绿假单胞菌引起的感染。头孢洛扎-他唑巴坦的总体安全性与其他抗菌药物相当，CDI的风险没有增加，与高肾毒性的抗菌药物相比具有明显优势。
